Peginterferon Alfa-2b
Pegylated interferon alfa-2b is a treatment for hepatitis C developed by Schering-Plough, brand name is PegIntron.
It was approved in January 2001.
It has also been approved as treatment for melanoma with nodal involvement after surgical resection, under the brand name Sylatron by Merck in April 2011.
PEG-interferon alpha is a pegylated interferon composed of 165 amino acids. The PEG (polyethylene glycol) protects the molecule from proteolytic breakdown and increases the biological half-life of the interferon protein. It is also used in patients with neurofibromatosis to shrink neurofibromas. Pegylated Interferon Alpha 2b is also used in the treatment of Myeloproliferative Neoplasms.
Read more about Peginterferon Alfa-2b: Mechanism of Action, Host Genetic Factors Influencing Treatment Response, See Also